{
    "Trade/Device Name(s)": [
        "LIAISON Anti-HAV",
        "LIAISON XL Analyzer",
        "LIAISON Control Anti-HAV"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K103529",
    "Predicate Device Reference 510(k) Number(s)": [
        "K082050",
        "K032844"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LOL",
        "JJF"
    ],
    "Summary Letter Date": "November 30, 2010",
    "Summary Letter Received Date": "December 1, 2010",
    "Submission Date": "November 30, 2010",
    "Regulation Number(s)": [
        "21 CFR 866.3310"
    ],
    "Regulation Name(s)": [
        "Hepatitis A virus (HAV) serological assays"
    ],
    "Analyte Class(es)": [
        "serology",
        "immunology",
        "virology"
    ],
    "Analyte(s)": [
        "Total antibodies to hepatitis A (anti-HAV)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Sodium heparin plasma"
    ],
    "Specimen Container(s)": [
        "Primary tube",
        "Aliquot tube",
        "Pediatric tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON Analyzer",
        "LIAISON XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Competitive sandwich CLIA",
        "Neutralization"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON Anti-HAV chemiluminescent immunoassay and XL Analyzer for qualitative detection of anti-HAV in human serum and plasma",
    "Indications for Use Summary": "Qualitative detection of total antibodies to hepatitis A (anti-HAV) in human serum and sodium heparin plasma; aids diagnosis of current or previous HAV infection and assessment of antibody response in vaccine recipients",
    "fda_folder": "Microbiology"
}